 | • レポートコード：MRC2-11QY03956 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は神経因性疼痛治療薬のグローバル市場について調査・分析したレポートです。種類別（三環系抗うつ薬抗けいれん薬、セロトニン・ノルエピネフリン再取り込み阻害薬、カプサイシンクリーム、局所麻酔薬、オピオイド、ステロイド、その他）市場規模、用途別（病院薬局、小売薬局、オンライン薬局）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別神経因性疼痛治療薬の競争状況、市場シェア ・世界の神経因性疼痛治療薬市場：種類別市場規模 2015年-2020年（三環系抗うつ薬抗けいれん薬、セロトニン・ノルエピネフリン再取り込み阻害薬、カプサイシンクリーム、局所麻酔薬、オピオイド、ステロイド、その他） ・世界の神経因性疼痛治療薬市場：種類別市場規模予測 2021年-2026年（三環系抗うつ薬抗けいれん薬、セロトニン・ノルエピネフリン再取り込み阻害薬、カプサイシンクリーム、局所麻酔薬、オピオイド、ステロイド、その他） ・世界の神経因性疼痛治療薬市場：用途別市場規模 2015年-2020年（病院薬局、小売薬局、オンライン薬局） ・世界の神経因性疼痛治療薬市場：用途別市場規模予測 2021年-2026年（病院薬局、小売薬局、オンライン薬局） ・北米の神経因性疼痛治療薬市場分析：米国、カナダ ・ヨーロッパの神経因性疼痛治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの神経因性疼痛治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の神経因性疼痛治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの神経因性疼痛治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、Johnson & Johnson、Sanofi、GlaxoSmithKline、Eli Lilly、Bristol-Myers Squibb、Biogen、Baxter Healthcare、Depomed ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Neuropathic pain is pain caused by damage or disease affecting the somatosensory nervous system. Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli (allodynia).
In terms of value, North America is a large market and is expected to increase at over 5% CAGR during the forecast period. The Asia Pacific neuropathic pain management market is projected to show fast growth and it is projected grow at CAGR of 6% over the forecast period due to increasing prevalence of diabetes in Asia Pacific, particularly in China and India.
Market Analysis and Insights: Global Neuropathic Pain Drugs Market
The global Neuropathic Pain Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Neuropathic Pain Drugs Scope and Market Size
Neuropathic Pain Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neuropathic Pain Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Pfizer
Johnson & Johnson
Sanofi
GlaxoSmithKline
Eli Lilly
Bristol-Myers Squibb
Biogen
Baxter Healthcare
Depomed
Market segment by Type, the product can be split into
Tricyclic Anti-Depressants Anticonvulsants
Serotonin-Norepinephrine Reuptake Inhibitor
Capsaicin Cream
Local Anaesthesia
Opioids
Steroids
Others
Market segment by Application, split into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Neuropathic Pain Drugs Revenue
1.4 Market by Type
1.4.1 Global Neuropathic Pain Drugs Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Tricyclic Anti-Depressants Anticonvulsants
1.4.3 Serotonin-Norepinephrine Reuptake Inhibitor
1.4.4 Capsaicin Cream
1.4.5 Local Anaesthesia
1.4.6 Opioids
1.4.7 Steroids
1.4.8 Others
1.5 Market by Application
1.5.1 Global Neuropathic Pain Drugs Market Share by Application: 2020 VS 2026
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Neuropathic Pain Drugs Market Perspective (2015-2026)
2.2 Global Neuropathic Pain Drugs Growth Trends by Regions
2.2.1 Neuropathic Pain Drugs Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Neuropathic Pain Drugs Historic Market Share by Regions (2015-2020)
2.2.3 Neuropathic Pain Drugs Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Neuropathic Pain Drugs Market Growth Strategy
2.3.6 Primary Interviews with Key Neuropathic Pain Drugs Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Neuropathic Pain Drugs Players by Market Size
3.1.1 Global Top Neuropathic Pain Drugs Players by Revenue (2015-2020)
3.1.2 Global Neuropathic Pain Drugs Revenue Market Share by Players (2015-2020)
3.1.3 Global Neuropathic Pain Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Neuropathic Pain Drugs Market Concentration Ratio
3.2.1 Global Neuropathic Pain Drugs Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Neuropathic Pain Drugs Revenue in 2019
3.3 Neuropathic Pain Drugs Key Players Head office and Area Served
3.4 Key Players Neuropathic Pain Drugs Product Solution and Service
3.5 Date of Enter into Neuropathic Pain Drugs Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Neuropathic Pain Drugs Historic Market Size by Type (2015-2020)
4.2 Global Neuropathic Pain Drugs Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Neuropathic Pain Drugs Market Size by Application (2015-2020)
5.2 Global Neuropathic Pain Drugs Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Neuropathic Pain Drugs Market Size (2015-2020)
6.2 Neuropathic Pain Drugs Key Players in North America (2019-2020)
6.3 North America Neuropathic Pain Drugs Market Size by Type (2015-2020)
6.4 North America Neuropathic Pain Drugs Market Size by Application (2015-2020)
7 Europe
7.1 Europe Neuropathic Pain Drugs Market Size (2015-2020)
7.2 Neuropathic Pain Drugs Key Players in Europe (2019-2020)
7.3 Europe Neuropathic Pain Drugs Market Size by Type (2015-2020)
7.4 Europe Neuropathic Pain Drugs Market Size by Application (2015-2020)
8 China
8.1 China Neuropathic Pain Drugs Market Size (2015-2020)
8.2 Neuropathic Pain Drugs Key Players in China (2019-2020)
8.3 China Neuropathic Pain Drugs Market Size by Type (2015-2020)
8.4 China Neuropathic Pain Drugs Market Size by Application (2015-2020)
9 Japan
9.1 Japan Neuropathic Pain Drugs Market Size (2015-2020)
9.2 Neuropathic Pain Drugs Key Players in Japan (2019-2020)
9.3 Japan Neuropathic Pain Drugs Market Size by Type (2015-2020)
9.4 Japan Neuropathic Pain Drugs Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Neuropathic Pain Drugs Market Size (2015-2020)
10.2 Neuropathic Pain Drugs Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Neuropathic Pain Drugs Market Size by Type (2015-2020)
10.4 Southeast Asia Neuropathic Pain Drugs Market Size by Application (2015-2020)
11 India
11.1 India Neuropathic Pain Drugs Market Size (2015-2020)
11.2 Neuropathic Pain Drugs Key Players in India (2019-2020)
11.3 India Neuropathic Pain Drugs Market Size by Type (2015-2020)
11.4 India Neuropathic Pain Drugs Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Neuropathic Pain Drugs Market Size (2015-2020)
12.2 Neuropathic Pain Drugs Key Players in Central & South America (2019-2020)
12.3 Central & South America Neuropathic Pain Drugs Market Size by Type (2015-2020)
12.4 Central & South America Neuropathic Pain Drugs Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Neuropathic Pain Drugs Introduction
13.1.4 Pfizer Revenue in Neuropathic Pain Drugs Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Details
13.2.2 Johnson & Johnson Business Overview
13.2.3 Johnson & Johnson Neuropathic Pain Drugs Introduction
13.2.4 Johnson & Johnson Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.2.5 Johnson & Johnson Recent Development
13.3 Sanofi
13.3.1 Sanofi Company Details
13.3.2 Sanofi Business Overview
13.3.3 Sanofi Neuropathic Pain Drugs Introduction
13.3.4 Sanofi Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.3.5 Sanofi Recent Development
13.4 GlaxoSmithKline
13.4.1 GlaxoSmithKline Company Details
13.4.2 GlaxoSmithKline Business Overview
13.4.3 GlaxoSmithKline Neuropathic Pain Drugs Introduction
13.4.4 GlaxoSmithKline Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.4.5 GlaxoSmithKline Recent Development
13.5 Eli Lilly
13.5.1 Eli Lilly Company Details
13.5.2 Eli Lilly Business Overview
13.5.3 Eli Lilly Neuropathic Pain Drugs Introduction
13.5.4 Eli Lilly Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.5.5 Eli Lilly Recent Development
13.6 Bristol-Myers Squibb
13.6.1 Bristol-Myers Squibb Company Details
13.6.2 Bristol-Myers Squibb Business Overview
13.6.3 Bristol-Myers Squibb Neuropathic Pain Drugs Introduction
13.6.4 Bristol-Myers Squibb Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.6.5 Bristol-Myers Squibb Recent Development
13.7 Biogen
13.7.1 Biogen Company Details
13.7.2 Biogen Business Overview
13.7.3 Biogen Neuropathic Pain Drugs Introduction
13.7.4 Biogen Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.7.5 Biogen Recent Development
13.8 Baxter Healthcare
13.8.1 Baxter Healthcare Company Details
13.8.2 Baxter Healthcare Business Overview
13.8.3 Baxter Healthcare Neuropathic Pain Drugs Introduction
13.8.4 Baxter Healthcare Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.8.5 Baxter Healthcare Recent Development
13.9 Depomed
13.9.1 Depomed Company Details
13.9.2 Depomed Business Overview
13.9.3 Depomed Neuropathic Pain Drugs Introduction
13.9.4 Depomed Revenue in Neuropathic Pain Drugs Business (2015-2020)
13.9.5 Depomed Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Neuropathic Pain Drugs Key Market Segments
Table 2. Key Players Covered: Ranking by Neuropathic Pain Drugs Revenue
Table 3. Ranking of Global Top Neuropathic Pain Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Neuropathic Pain Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Tricyclic Anti-Depressants Anticonvulsants
Table 6. Key Players of Serotonin-Norepinephrine Reuptake Inhibitor
Table 7. Key Players of Capsaicin Cream
Table 8. Key Players of Local Anaesthesia
Table 9. Key Players of Opioids
Table 10. Key Players of Steroids
Table 11. Key Players of Others
Table 12. Global Neuropathic Pain Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 13. Global Neuropathic Pain Drugs Market Size by Regions (US$ Million): 2020 VS 2026
Table 14. Global Neuropathic Pain Drugs Market Size by Regions (2015-2020) (US$ Million)
Table 15. Global Neuropathic Pain Drugs Market Share by Regions (2015-2020)
Table 16. Global Neuropathic Pain Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 17. Global Neuropathic Pain Drugs Market Share by Regions (2021-2026)
Table 18. Market Top Trends
Table 19. Key Drivers: Impact Analysis
Table 20. Key Challenges
Table 21. Neuropathic Pain Drugs Market Growth Strategy
Table 22. Main Points Interviewed from Key Neuropathic Pain Drugs Players
Table 23. Global Neuropathic Pain Drugs Revenue by Players (2015-2020) (Million US$)
Table 24. Global Neuropathic Pain Drugs Market Share by Players (2015-2020)
Table 25. Global Top Neuropathic Pain Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuropathic Pain Drugs as of 2019)
Table 26. Global Neuropathic Pain Drugs by Players Market Concentration Ratio (CR5 and HHI)
Table 27. Key Players Headquarters and Area Served
Table 28. Key Players Neuropathic Pain Drugs Product Solution and Service
Table 29. Date of Enter into Neuropathic Pain Drugs Market
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$)
Table 32. Global Neuropathic Pain Drugs Market Size Share by Type (2015-2020)
Table 33. Global Neuropathic Pain Drugs Revenue Market Share by Type (2021-2026)
Table 34. Global Neuropathic Pain Drugs Market Size Share by Application (2015-2020)
Table 35. Global Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$)
Table 36. Global Neuropathic Pain Drugs Market Size Share by Application (2021-2026)
Table 37. North America Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$)
Table 38. North America Key Players Neuropathic Pain Drugs Market Share (2019-2020)
Table 39. North America Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$)
Table 40. North America Neuropathic Pain Drugs Market Share by Type (2015-2020)
Table 41. North America Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$)
Table 42. North America Neuropathic Pain Drugs Market Share by Application (2015-2020)
Table 43. Europe Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$)
Table 44. Europe Key Players Neuropathic Pain Drugs Market Share (2019-2020)
Table 45. Europe Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$)
Table 46. Europe Neuropathic Pain Drugs Market Share by Type (2015-2020)
Table 47. Europe Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$)
Table 48. Europe Neuropathic Pain Drugs Market Share by Application (2015-2020)
Table 49. China Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$)
Table 50. China Key Players Neuropathic Pain Drugs Market Share (2019-2020)
Table 51. China Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$)
Table 52. China Neuropathic Pain Drugs Market Share by Type (2015-2020)
Table 53. China Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$)
Table 54. China Neuropathic Pain Drugs Market Share by Application (2015-2020)
Table 55. Japan Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$)
Table 56. Japan Key Players Neuropathic Pain Drugs Market Share (2019-2020)
Table 57. Japan Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$)
Table 58. Japan Neuropathic Pain Drugs Market Share by Type (2015-2020)
Table 59. Japan Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$)
Table 60. Japan Neuropathic Pain Drugs Market Share by Application (2015-2020)
Table 61. Southeast Asia Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$)
Table 62. Southeast Asia Key Players Neuropathic Pain Drugs Market Share (2019-2020)
Table 63. Southeast Asia Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$)
Table 64. Southeast Asia Neuropathic Pain Drugs Market Share by Type (2015-2020)
Table 65. Southeast Asia Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$)
Table 66. Southeast Asia Neuropathic Pain Drugs Market Share by Application (2015-2020)
Table 67. India Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$)
Table 68. India Key Players Neuropathic Pain Drugs Market Share (2019-2020)
Table 69. India Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$)
Table 70. India Neuropathic Pain Drugs Market Share by Type (2015-2020)
Table 71. India Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$)
Table 72. India Neuropathic Pain Drugs Market Share by Application (2015-2020)
Table 73. Central & South America Key Players Neuropathic Pain Drugs Revenue (2019-2020) (Million US$)
Table 74. Central & South America Key Players Neuropathic Pain Drugs Market Share (2019-2020)
Table 75. Central & South America Neuropathic Pain Drugs Market Size by Type (2015-2020) (Million US$)
Table 76. Central & South America Neuropathic Pain Drugs Market Share by Type (2015-2020)
Table 77. Central & South America Neuropathic Pain Drugs Market Size by Application (2015-2020) (Million US$)
Table 78. Central & South America Neuropathic Pain Drugs Market Share by Application (2015-2020)
Table 79. Pfizer Company Details
Table 80. Pfizer Business Overview
Table 81. Pfizer Product
Table 82. Pfizer Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$)
Table 83. Pfizer Recent Development
Table 84. Johnson & Johnson Company Details
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Product
Table 87. Johnson & Johnson Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$)
Table 88. Johnson & Johnson Recent Development
Table 89. Sanofi Company Details
Table 90. Sanofi Business Overview
Table 91. Sanofi Product
Table 92. Sanofi Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$)
Table 93. Sanofi Recent Development
Table 94. GlaxoSmithKline Company Details
Table 95. GlaxoSmithKline Business Overview
Table 96. GlaxoSmithKline Product
Table 97. GlaxoSmithKline Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$)
Table 98. GlaxoSmithKline Recent Development
Table 99. Eli Lilly Company Details
Table 100. Eli Lilly Business Overview
Table 101. Eli Lilly Product
Table 102. Eli Lilly Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$)
Table 103. Eli Lilly Recent Development
Table 104. Bristol-Myers Squibb Company Details
Table 105. Bristol-Myers Squibb Business Overview
Table 106. Bristol-Myers Squibb Product
Table 107. Bristol-Myers Squibb Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$)
Table 108. Bristol-Myers Squibb Recent Development
Table 109. Biogen Company Details
Table 110. Biogen Business Overview
Table 111. Biogen Product
Table 112. Biogen Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$)
Table 113. Biogen Recent Development
Table 114. Baxter Healthcare Business Overview
Table 115. Baxter Healthcare Product
Table 116. Baxter Healthcare Company Details
Table 117. Baxter Healthcare Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$)
Table 118. Baxter Healthcare Recent Development
Table 119. Depomed Company Details
Table 120. Depomed Business Overview
Table 121. Depomed Product
Table 122. Depomed Revenue in Neuropathic Pain Drugs Business (2015-2020) (Million US$)
Table 123. Depomed Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuropathic Pain Drugs Market Share by Type: 2020 VS 2026
Figure 2. Tricyclic Anti-Depressants Anticonvulsants Features
Figure 3. Serotonin-Norepinephrine Reuptake Inhibitor Features
Figure 4. Capsaicin Cream Features
Figure 5. Local Anaesthesia Features
Figure 6. Opioids Features
Figure 7. Steroids Features
Figure 8. Others Features
Figure 9. Global Neuropathic Pain Drugs Market Share by Application: 2020 VS 2026
Figure 10. Hospital Pharmacies Case Studies
Figure 11. Retail Pharmacies Case Studies
Figure 12. Online Pharmacies Case Studies
Figure 13. Neuropathic Pain Drugs Report Years Considered
Figure 14. Global Neuropathic Pain Drugs Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Neuropathic Pain Drugs Market Share by Regions: 2020 VS 2026
Figure 16. Global Neuropathic Pain Drugs Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Neuropathic Pain Drugs Market Share by Players in 2019
Figure 19. Global Top Neuropathic Pain Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuropathic Pain Drugs as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Neuropathic Pain Drugs Revenue in 2019
Figure 21. North America Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Neuropathic Pain Drugs Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Bottom-up and Top-down Approaches for This Report
Figure 29. Data Triangulation
Figure 30. Key Executives Interviewed
変形性関節症鎮痛薬の世界市場（～2026年） Drugs for Osteoarthritis Pain market, the main role of osteoarthritis pain drugs is to relieve pain, and cannot slow the progress of osteoarthritis. Geographically, the global Drugs for Osteoarthritis Pain market has been segmented into North America, Europe, China, Japan, Rest of Asia (RoA), and Re…- 疼痛管理治療薬の世界市場（～2026年） Market Analysis and Insights: Global Pain Management Therapeutics Market The global Pain Management Therapeutics market size is projected to reach US$ 59160 million by 2026, from US$ 57740 million in 2020, at a CAGR of 2.3%% during 2021-2026. Global Pain Management Therapeutics Scope and Market Size…
- 動物疼痛管理薬の世界市場（～2026年） Market Analysis and Insights: Global Veterinary Pain Management Drugs Market The global Veterinary Pain Management Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Veterinary Pain Management Drugs Scope and Market…
- 痛み・発熱緩和薬の世界市場（～2026年） The demand for Pain and Fever Relief Drugs will continue to grow in the next few years. Market Analysis and Insights: Global Pain and Fever Relief Drugs Market The global Pain and Fever Relief Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of X…
- 術後疼痛管理の世界市場（～2026年） Postoperative pain management aims to minimise patient discomfort, facilitate early mobilization and functional recovery, and prevent acute pain developing into chronic pain. Mental health can affect a patient’s recovery and psychological vulnerability is predictive of severe postoperative pain. Edu…